The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients

Chao Li1 · Mengdong Zhang2 · Jianwen Wang2 · Xiaodong Zhang2

Received: 16 August 2021 / Accepted: 23 September 2021 / Published online: 12 February 2022 © The Author(s) 2022

Summary

Objective To compare the efficacy and safety-related outcomes after radical prostatectomy (RP) and permanent seed implantation (PI) using iodine-125 seeds in patients with prostate cancer. Method A retrospective analysis of 196 patients with biopsy-confirmed prostate cancer (T2-T3) was performed in this study. Forty-five patients who underwent PI using iodine-125 seeds combined with endocrine therapy or androgen deprivation therapy (ADT) were compared with 151 patients who underwent RP combined with endocrine therapy or adjuvant ADT. The efficacy and safety outcomes were compared using Kaplan–Meier curves and t-tests. Results Between the RP and PI treatment modalities, no significant difference (P > 0.05) in biochemical recurrence-free survival (BRFS) was observed using Kaplan–Meier curves, regardless of the combination of adjuvant treatment modalities. Furthermore, no significant differences were observed (P > 0.05) with respect to PSA fluctuations, albumin, leukocyte count, urinary and rectal symptoms, erectile function or quality of life (QoL) between the two therapy methods. However, significant differences in the maximum flow rate, average length of hospital stay and indwelling catheter time were observed between the two groups (P < 0.001). Conclusion Iodine-125 seed implantation significantly shortened the average length of hospital stay and indwelling catheter time compared with RP, and the haemoglobin level was significantly higher in the PI group than in the RP group; however, the maximum urine flow rate was lower after of PI than after RP. These two methods showed similar BRFS rates among prostate cancer patients.

Keywords Permanent seed implantation · Radical prostatectomy · Survival rate · Security · Efficacy

Introduction

Prostate cancer is the most common cancer among males, and the incidence is in increasing [1]. By screening PSA levels, prostate tumours confined to the prostate gland can be diagnosed at an early stage. Prostate cancer patients face a confusing choice between radical prostatectomy (RP) and brachytherapy. Radical prostatectomy is considered to be the gold standard and an effective therapy choice for localized prostate cancer [2]. The most popular technique for brachytherapy is permanent seed implantation, and the most commonly used isotope is iodine-125[3]. Brachytherapy has been shown to be relatively minimally invasive, lead to a reduced morbidity and is associated with a minimal length of hospital stay[4]; furthermore, more than 80% of patients are free from biochemical recurrence within 10 years[5]. A large amount of data from the United States also showed that brachytherapy with permanent seeds was an effective treatment for patients with localized prostate cancer[6]. Previous reports [3, 7] also suggested that RP and brachytherapy treatments were equivalent in biochemical control; however, a comparison safety between these two methods remains to be performed. In the present study, we aimed to compare BRFS and safety-related parameters in prostate cancer patients treated with RP or PI at a single hospital.

Materials and methods

Patients

From November 2013 to January 2017, 196 patients who were diagnosed pathologically with prostate cancer through
transrectal ultrasound-guided biopsies of the prostate (T2-3) at our institution were enrolled in this study. All patients in this study were consecutive patients. None of the patients had other urinary system diseases or prior operations. Forty-five patients underwent PI, and 151 patients were treated with RP; the choice of therapy type was made by both the doctor and the patient. All RP and PI treatments were performed by the same surgeon. Patients without previous treatment, follow-up PSA levels and Gleason scores were excluded from this study. Distant metastasis and lymphatic metastasis cases were also excluded from this study. In the PI group, 15 patients also received endocrine therapy preoperatively, and 13 received ADT therapy postoperatively, while 52 and 44 patients received endocrine therapy and ADT therapy in the RP group, respectively. All RP and PI treatments were performed by the same surgeon. Patients without previous treatment, follow-up PSA levels and Gleason scores were excluded from this study. Distant metastasis and lymphatic metastasis cases were also excluded from this study. In the PI group, 15 patients also received endocrine therapy preoperatively, and 13 received ADT therapy postoperatively, while 52 and 44 patients received endocrine therapy and ADT therapy in the RP group, respectively. All data were obtained from a prospectively maintained database. All patients enrolled in this study provided signed informed consent forms, and our research was approved by the ethics committee of our institution.

All patients were evaluated based on medical history, biopsies of the prostate using transrectal ultrasound guidance, pre-treatment PSA level (iPSA), digital rectal examinations, bone scans using computed tomography and serum chemistry examinations.

**PI and RP therapies**

In the present study, the PI therapy procedures were similar to those in previous reports[3, 6]. Briefly, the dimensions of each prostate were measured through transrectal ultrasonography pre brachytherapy to confirm the overall isotope activity required for each patient, and the number of seeds required for implantation was calculated by dividing the overall activity required by the activity of each seed at the implant point. The target area was a 5-mm margin around the lateral and anterior prostate. The seeds were then introduced to their target positions by the radiation oncologist and urologist. The radical prostatectomy procedures were similar to the approach used in previous reports [3, 8].

### Results

The baseline characteristics of the prostate cancer patients in the present research are shown in Tables 1 and 2. The patients who underwent permanent seed implantation had an age range of 58–85 years (mean 74.8 ± 6.3), while the patients treated with radical prostatectomy were aged 27–87 years, with a mean of 72.5 ± 7.9 years (P = 0.25). No significant differences were observed with respect to BMI, iPSA, Gleason score, prostate volume, maximum tumour load or clinical stage between the two cohorts (P > 0.05). Furthermore, the results of conventional physical

| Table 1 Baseline characteristics |
|----------------------------------|
| **PI** (N=45) | **RP** (N=151) | **P-value** |
| Mean age ± SD (years) | 74.8 ± 6.3 (58–85) | 72.5 ± 7.9 (27–87) | 0.25 |
| Mean BMI (kg/m²) | 24.8 ± 3.1 | 24.3 ± 3.3 | 0.18 |
| iPSA (ug/ml) | 21.6 ± 18.1 | 24.4 ± 10.1 | 0.60 |
| Mean prostate volume ± SD (ml) | 48.3 ± 23.5 | 45.2 ± 17.1 | 0.43 |
| Mean Gleason score | 7.5 ± 1.1 | 7.6 ± 2.1 | 0.74 |
| Number of positive needles | 2.5 ± 1.5 | 2.7 ± 1.8 | 0.84 |
| Maximum tumour load (%) | 39.2 ± 19.0 | 41.2 ± 14.1 | 0.66 |

PI and RP represent permanent seed implantation and radical prostatectomy, respectively. P < 0.05 represent a significant difference between the PI and RP groups.
control after PI and RP was monitored by evaluating serum PSA fluctuations at 1, 6, 12, 24 and 36 months of follow-up. The biochemical recurrence-free survival rates of the patients with and without adjuvant therapies were further analyzed, and the log-rank test showed no statistically significant difference was observed between the prostate cancer patients with and without neoadjuvant hormone/ADP therapies in RP group ($P = 0.89$) (Fig. 2A and B), between the PI treated patients with and without neoadjuvant hormone/ADP therapies ($P = 0.50$ and $P = 0.071$), respectively (Fig. 2C and D). As shown in Fig. 3, the patients in both the PI and RP groups had a continuous reduction in PSA postoperatively. Three years after PI treatment, the PSA levels decreased from 18.2 to 0.7 ng/ml.

The PI group had a significantly lower maximum urine flow rate, shorter average length of hospital stay and shorter indwelling catheterization time than those in the RP group ($P < 0.05$), and the haemoglobin level was significantly higher in the PI group than in the RP group ($P < 0.05$). However, no significant difference existed between the two treatments with respect to WBC count, albumin and haemoglobin level ($P > 0.05$). Furthermore, the QoL and IIEF scores were $52.0 \pm 5.6$ and $23.4 \pm 1.2$ in the PI group and $50.7 \pm 6.2$ and $21.2 \pm 3.5$ in the RP group, respectively, and no significant difference was found between these two treatments ($P > 0.05$) (Table 3).

### Discussion

Radical prostatectomy is the gold standard therapy for localized prostate cancer because of its superior cure rate[7]. With the development of radiation therapy and radiological technology, the positive outcomes after permanent seed implantation have improved in recent years compared with previous reports[9]. Many studies have compared the BRFS rates of prostate cancer patients treated with RP, PI and external-beam radiotherapy. However, safety-related outcomes remain to be established. In this study, we compared the efficacy and safety of radical prostatectomy and permanent seed implantation, including pain relief, psychological and physiological burden and degree of satisfaction with the therapeutic effects.

It was reported that the survival rate of patients treated with brachytherapy (79.7%) was higher than that of patients treated with radical prostatectomy (44.3%)[3]; however, many previous studies[7, 10] also showed that the biochemical failure rates between radical prostatectomy and permanent prostate brachytherapy were similar. Our results revealed that the biochemical recurrence-free survival of all patients between the two therapies was similar, with no significant difference ($P > 0.05$). The effects of brachytherapy on prostate cancer were heterogeneous and

| Table 2 Main clinical parameters of the physical examination | PI n (%) | RP n (%) | $P$-value |
|-----------------------------------------------------------|----------|----------|-----------|

| Clinical stage       |          |          | 0.34      |
|----------------------|----------|----------|-----------|
| 2a                   | 8 (17.8) | 16 (10.6) |           |
| 2b                   | 8 (17.8) | 39 (25.8) |           |
| 2c                   | 17 (37.8)| 42 (27.8) |           |
| 3a                   | 11 (24.4)| 47 (31.1) |           |
| 3b                   | 1 (2.2)  | 7 (4.7)   |           |

| Bone scintigraphy   |          |          | 0.67      |
|----------------------|----------|----------|-----------|
| Normal               | 31 (68.9)| 109 (72.2)|           |
| Abnormal             | 14 (31.1)| 42 (27.8) |           |

| Hypertension         |          |          | 0.28      |
|----------------------|----------|----------|-----------|
| No                   | 35 (77.8)| 105 (69.5)|           |
| Yes                  | 10 (22.2)| 46 (30.5) |           |

| Diabetes mellitus    |          |          | 0.19      |
|----------------------|----------|----------|-----------|
| No                   | 35 (77.8)| 102 (67.5)|           |
| Yes                  | 10 (22.2)| 49 (32.5) |           |

| Neoadjuvant endocrine therapy |          |          | 0.89      |
|-------------------------------|----------|----------|-----------|
| No                            | 30 (66.7)| 99 (65.6) |           |
| Yes                           | 15 (33.3)| 52 (34.4) |           |

| ADT therapy                  |          |          | 0.97      |
|-------------------------------|----------|----------|-----------|
| No                            | 32 (71.1)| 107 (70.9)|           |
| Yes                           | 13 (28.9)| 44 (29.1) |           |

| Digital rectal examination   |          |          | 0.46      |
|-------------------------------|----------|----------|-----------|
| Negative                      | 16 (35.6)| 63 (41.7) |           |
| Positive                      | 29 (64.4)| 88 (58.3) |           |

| MRI                           |          |          | 0.91      |
|-------------------------------|----------|----------|-----------|
| Negative                      | 12 (26.7)| 39 (25.8) |           |
| Positive                      | 33 (73.3)| 112 (74.2)|           |
Fig. 1 Kaplan–Meier estimates of biochemical relapse-free survival according to treatment modality for patients with prostate cancer. PI, permanent seed implantation; RP, radical prostatectomy. A BRFS over a 45-month period for the entire cohort that underwent PI (45 patients) and RP (151 patients); $P=0.89$, representing no significant difference. B and C Survival curves for the entire cohort with B and without C adjuvant endocrine therapy. D and E Survival curves for the entire cohort with D and without E adjuvant ADT treatment. PI, RP, ADT represent permanent seed implantation, radical prostatectomy and androgen deprivation therapy, respectively. $P=0.87$ and $P=0.85$ represent no significant differences in BRFS between the PI and RP groups stratified by adjuvant endocrine therapy and ADT, respectively.
were possibly associated with brachytherapy technique and differences in methodology to compare the outcomes of surgery and brachytherapy. It was also reported that biochemical recurrence-free survival was determined more by the intrinsic characteristics of the tumour than by a specific therapy modality at the time of treatment [11]; thus, the tumour characteristics before therapy are associated with the treatment outcomes.

It was reported that the combination of multimodality treatment, including ADT, showed a higher progression-free survival than seed implantation or surgery alone for prostate cancer patients [7]. In the present study, 15 and 13 patients were treated with PI therapy combined with neoadjuvant endocrine therapy or ADT, respectively, and 52 and 44 patients underwent RP therapy combined with neoadjuvant endocrine therapy or ADT, respectively. Our results showed similar Kaplan–Meier curves for BRFS in prostate cancer patients treated with PI or RP combined with or without neoadjuvant endocrine therapy or ADT, indicating that no significant differences (P > 0.05) in BRFS were observed between the PI and RP groups, regardless of treatment with monotherapy alone or combined adjuvant therapies.

A comparison of the safety-related outcomes after radical prostatectomy and permanent seed implantation using iodine-125 seed groups has not been performed. Tanake et al. [12] analysed acute and late genitourinary (GU) toxicity in prostate cancer patients who underwent PI therapy and revealed that PI therapy alone induced a significantly...
higher rate of GU toxicity than PI combined with external-beam radiation therapy. The acute effects of permanent brachytherapy on the urinary tract include urge incontinence, urgency of urination, haematuria, painful micturition and urinary retention [13]. In line with previous studies, our results also showed that the maximum urine flow rate in the seed implantation group was $14.7 \pm 3.4$ ml/s, which was significantly lower than that after radical prostatectomy treatment ($23.4 \pm 2.0$ ml/s) ($P < 0.05$), which may be because gland retention and tissue oedema after seed implantation are associated with the maximum urine flow rate.

In this study, the average length of hospital stay and indwelling catheterization time of patients who underwent permanent seed implantation were $3.7 \pm 1.5$ and $3.2 \pm 1.2$ days, respectively, which were significantly shorter than those in patients who underwent radical prostatectomy ($7.7 \pm 3.5$ and $10.4 \pm 6.2$ days, respectively) ($P < 0.001$), indicating that the recovery period of seed implantation was shorter than that of radical prostatectomy.

Currently, the clinical curative evaluation is not limited to efficiency, safety and pain relief rate but rather includes a comprehensive patient evaluation, including satisfaction degree, psychological and mental state, as well as recovery of social functions[14]. Thus, the postoperative quality of life in patients treated with seed implantation and radical prostatectomy was studied using the QoL score in this study, and our results showed that no significant difference existed between the seed implantation and radical prostatectomy groups ($P > 0.05$), which was not in line with previous reports[7, 15] that revealed that the quality of life after seed implantation was better than that after radical prostatectomy. In our future research, we aim to determine the incidence of complications after radical prostatectomy and permanent seed implantation treatments with a larger cohort of patients. Erectile dysfunction is a therapy-induced morbidity; Merrick et al.[16] evaluated erectile function after permanent brachytherapy using IIEF and showed that the incidence rate of erectile dysfunction was 52% at 6 years, and the potency rate was 55% at 2 years according to a telephone-administered questionnaire by Chaikin et al. [17]. In the present study, we compared the IIEF scores between the permanent seed implantation ($23.4 \pm 1.2$) and radical prostatectomy groups ($21.2 \pm 3.5$), and no significant difference was observed between these two treatments ($P > 0.05$), indicating that the two treatments led to similar sexual function impairment.

Table 3 Safety-related parameters of patients who underwent PI and RP

| Postoperative variables          | PI (N=45) | RP (N=151) | P-value |
|---------------------------------|-----------|------------|---------|
| Maximum urine flow rate (ml/s)  | 14.7±3.4  | 23.4±2.0   | 0       |
| Average length of hospital stay (days) | 3.7±1.5  | 7.7±3.5   | 0       |
| Indwelling catheterization (days) | 3.2±1.2  | 10.4±6.2  | 0       |
| QoL                             | 52.0±5.6  | 50.7±6.2   | 0.84    |
| IIEF score                      | 23.4±1.2  | 21.2±3.5   | 0.61    |
| Haemoglobin (g/L)               | 112.0±24.1| 90.2±18.3  | 0.02    |
| WBC (*10⁹)                      | 6.3±1.3   | 7.8±2.3    | 0.1     |
| Albumin (g/L)                   | 41.3±7.2  | 36.2±9.2   | 0.26    |

PI and RP represent permanent seed implantation and radical prostatectomy, respectively. QoL and WBC indicate quality of life and white blood cell, respectively

To the best of our knowledge, few studies have compared haemoglobin, leucocyte and albumin levels postoperatively between permanent seed implantation and radical prostatectomy, as we have in this study. Our results showed that no significant difference ($P > 0.05$) in leucocyte and albumin existed between the two groups after treatments. However, the average haemoglobin level after
radical prostatectomy was 90.2 ± 18.3, which was significantly lower \( (P < 0.001) \) than that after seed implantation \( (112.0 ± 24.1) \). Haemoglobin level will be studied in our future study with longer postoperative follow-up.

**Conclusions**

In prostate cancer patients, permanent seed implantation using iodine-125 seeds resulted in similar biochemical recurrence-free survival to radical prostatectomy, regardless of the use of adjuvant multimodality treatments. However, the safety-related physiological parameters revealed significant differences between the two therapy methods.

**Acknowledgements** The authors thank Dr. Xuejing Zhang of Shiji-zhuang First Hospital for revising the manuscript.

**Authors’ contributions** Xiaodong Zhang designed and conducted the study. Jianwen Wang collected and analyzed clinical data. Chao Li and Mengdong Zhang wrote and revised the manuscript.

**Funding** This work was supported by Beijing Natural Science Foundation (7182058).

**Data availability** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate** This evaluation was conducted in agreement with the guidelines of the Ethics Committee of Beijing ChaoYang Hospital. All patients have written informed consent.

**Consent for publication** Not applicable.

**Competing interests** The authors declare that they have no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Pons-Llanas O, Roldan-Ortega S, Celada-Alvarez F, Perez-Calatayud MJ, Fornes-Ferrer V, Tormo-Mico A, Perez-Calatayud J, Lopez-Torrecilla JL (2018) Permanent seed implant brachytherapy in low-risk prostate cancer: Preoperative planning with 145Gy versus real-time intraoperative planning with 160Gy. Rep Pract Oncol Radiother 23:290–297
2. Gaztanaga M, Crook JM (2013) Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature. Brachytherapy 12:338–342
3. Ferreira AS, Guerra MR, Lopes HE, Lima UT, Vasconcelos YA, Teixeira MT (1992) Brachytherapy and radical prostatectomy in patients with early prostate cancer. Rev Assoc Med Bras 61(2015):431–439
4. Kohan AD, Armenakas NA, Fracchia JA (2000) The perioperative charge equivalence of interstitial brachytherapy and radical prostatectomy with 1-year follow-up. J Urol 163:511–514
5. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W (2001) 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51:31–40
6. Saito S, Nagata H, Kosugi M, Toya K, Yorozu A (2007) Brachytherapy with permanent seed implantation. Int J Clin Oncol 12:395–407
7. Park DS, Gong IH, Choi DK, Hwang JH, Shin HS, Oh JJ (2013) Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis. World J Urol 31:1511–1517
8. Comploj E, Pycha A (2012) Experience with radical perineal prostatectomy in the treatment of localized prostate cancer. Ther Adv Urol 4:125–131
9. Guinot JL, Ricos JV, Tortajada ML, Santos MA, Casanova J, Clemente J, Samper J, Santamaria P, Arribas L (2015) Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer. J Contemp Brachytherapy 7:258–264
10. Potters L, Klein EA, Kattan MW, Reddy CA, Czieki JP, Reuther AM, Kupelian PA (2004) Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29–33
11. Kupelian PA, Potters L, Khuntia D, Czieki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33
12. N. Tanaka, A. Yorozu, T. Kikuchi, S. Higashide, S. Kojima, T. Ohashi, N. Katayama, K. Nakamura, S. Saito, T. Dokiyama, M. Fukushima, J.P.S. Group (2019) Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). Brachytherapy 18:484–492
13. Borchers H, Kirscher-Hermanns R, Brehmer B, Tietzle L, Reineke T, Pinkawa M, Eble MJ, Jakse G (2004) Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU Int 94:805–811
14. Luo Y, He M, Li C, Yang H (2019) A research on quality of life score (QOLS) of patients with trigeminal neuralgia (TN). J Infect Public Health 12:690–694
15. Crook JM, Gomez-Itrurriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleschner N (2011) Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 29:362–368
16. Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH (2002) Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52:893–902
17. Chaikin DC, Broderick GA, Malloy TR, Malkowicz SB, Whittington R, Wein AJ (1996) Erectile dysfunction following minimally invasive treatments for prostate cancer. Urology 48:100–104

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.